Doberstein Stephen K

SEC source: 0001480111-26-000003 · form4-08272026_080805.xml · derivative · entry 6

Doberstein Stephen K · CIK 0001480111 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 18,353 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.

F4 · price: Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger.

F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger.

F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger.

SEC source: 0001480111-26-000003 · form4-08272026_080805.xml · derivative · entry 5

Doberstein Stephen K · CIK 0001480111 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 31,000 shares

Expires 2035-03-20

F1 · price: Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share ("Merger Consideration"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent.

F2 · price: At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor.

F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share ("Merger Consideration"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent.

F2 · derivative.exercise_date: At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor.

SEC source: 0001480111-26-000003 · form4-08272026_080805.xml · derivative · entry 4

Doberstein Stephen K · CIK 0001480111 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,000 shares

Expires 2034-08-20

F1 · price: Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share ("Merger Consideration"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent.

F2 · price: At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor.

SEC source: 0001480111-26-000003 · form4-08272026_080805.xml · derivative · entry 3

Doberstein Stephen K · CIK 0001480111 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,000 shares

Expires 2033-09-19

F1 · price: Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share ("Merger Consideration"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent.

F2 · price: At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor.

SEC source: 0001480111-26-000003 · form4-08272026_080805.xml · derivative · entry 2

Doberstein Stephen K · CIK 0001480111 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,000 shares

Expires 2032-06-01

F1 · price: Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share ("Merger Consideration"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent.

F2 · price: At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor.

SEC source: 0001480111-26-000003 · form4-08272026_080805.xml · derivative · entry 1

Doberstein Stephen K · CIK 0001480111 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,000 shares

Expires 2032-05-12

F1 · price: Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share ("Merger Consideration"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent.

F2 · price: At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor.

SEC source: 0001480111-26-000002 · form4-06022026_080622.xml · derivative · entry 1

Doberstein Stephen K · CIK 0001480111 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,353

Underlying: Common Stock · 18,353 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.

F2 · derivative.exercise_date: Subject to the Reporting Person's continuing as a Service Provider (as defined in the 2021 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the date of the first annual meeting of the stockholders that occurs after May 29, 2026.

F2 · derivative.expiration_date: Subject to the Reporting Person's continuing as a Service Provider (as defined in the 2021 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the date of the first annual meeting of the stockholders that occurs after May 29, 2026.

SEC source: 0001415889-25-008782 · form4-03212025_080357.xml · derivative · entry 1

Doberstein Stephen K · CIK 0001480111 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,000

Underlying: Common Stock · 31,000 shares

Expires 2035-03-20

F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over a three (3) year period such that the option shall be fully vested on the third (3rd) anniversary of the Date of Grant. "Date of Grant" shall mean March 20, 2025.

SEC source: 0001415889-24-022002 · form4-08222024_080819.xml · derivative · entry 1

Doberstein Stephen K · CIK 0001480111 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2034-08-20

F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the twelve (12) months following the Date of Grant, provided that the shares subject to the option shall be fully vested on the date of the Issuer's next annual stockholder meeting. "Date of Grant" shall mean August 20, 2024.

SEC source: 0001209191-23-050190 · doc4.xml · derivative · entry 1

Doberstein Stephen K · CIK 0001480111 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2033-09-19

F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the twelve (12) months following the Date of Grant, provided that the shares subject to the option shall be fully vested on the date of the Issuer's next annual stockholder meeting. "Date of Grant" shall mean September 19, 2023.

SEC source: 0001209191-22-033612 · doc4.xml · derivative · entry 1

Doberstein Stephen K · CIK 0001480111 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2032-06-01

F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the twelve (12) months following the Date of Grant, provided that the shares subject to the option shall be fully vested on the date of the Issuer's next annual stockholder meeting. "Date of Grant" shall mean June 1, 2022.

SEC source: 0001209191-22-029225 · doc4.xml · derivative · entry 1

Doberstein Stephen K · CIK 0001480111 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2032-05-12

F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the thirty six (36) months following the Date of Grant, such that the shares subject to the option shall be fully vested on the third (3rd) anniversary of the Date of Grant. "Date of Grant" shall mean May 12, 2022.

SEC source: 0001399529-21-000197 · wf-form4_164081275082632.xml · derivative · entry 5

Doberstein Stephen K · CIK 0001480111 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires not disclosed

F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting).

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting).

F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting).

SEC source: 0001399529-21-000197 · wf-form4_164081275082632.xml · derivative · entry 4

Doberstein Stephen K · CIK 0001480111 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires not disclosed

F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting).

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting).

F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting).

SEC source: 0001399529-21-000197 · wf-form4_164081275082632.xml · derivative · entry 3

Doberstein Stephen K · CIK 0001480111 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,000 shares

Expires not disclosed

F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting).

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting).

F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting).

SEC source: 0001399529-21-000197 · wf-form4_164081275082632.xml · derivative · entry 2

Doberstein Stephen K · CIK 0001480111 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,333 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one Share.

F3 · price: At the Effective Time, each Issuer RSU that was then outstanding was cancelled and converted into the right to receive a cash payment equal to (A) the Offer Price multiplied by (B) the total number of Shares subject to such Issuer RSU immediately prior to the Effective Time (without regard to vesting).

F3 · derivative.exercise_date: At the Effective Time, each Issuer RSU that was then outstanding was cancelled and converted into the right to receive a cash payment equal to (A) the Offer Price multiplied by (B) the total number of Shares subject to such Issuer RSU immediately prior to the Effective Time (without regard to vesting).

F3 · derivative.expiration_date: At the Effective Time, each Issuer RSU that was then outstanding was cancelled and converted into the right to receive a cash payment equal to (A) the Offer Price multiplied by (B) the total number of Shares subject to such Issuer RSU immediately prior to the Effective Time (without regard to vesting).

SEC source: 0001399529-21-000197 · wf-form4_164081275082632.xml · nonDerivative · entry 1

Doberstein Stephen K · CIK 0001480111 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.0001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of December 28, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $38.25 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.

F1 · shares: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.0001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of December 28, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $38.25 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.0001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of December 28, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $38.25 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.

SEC source: 0001399529-21-000104 · wf-form4_162311596214632.xml · derivative · entry 4

Doberstein Stephen K · CIK 0001480111 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2031-06-02

F4 · derivative.exercise_date: This option vests monthly over 12 months from the Grant Date in substantially equal monthly installments, provided that the option will vest in full on the next regularly scheduled annual meeting of the stockholders of the Issuer that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer as a director through each such date or, if earlier, such annual meeting.

SEC source: 0001399529-21-000104 · wf-form4_162311596214632.xml · derivative · entry 3

Doberstein Stephen K · CIK 0001480111 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,333

Underlying: Common Stock · 3,333 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Common Stock.

F3 · derivative.exercise_date: Represents RSUs that shall vest and become nonforfeitable with respect to one-hundred percent (100%) of the total number of RSUs on the earlier of (i) 12 months from June 3, 2021 ("Grant Date") and (ii) the next regularly scheduled annual meeting of stockholders of the Issuer that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer as a director through such date or, if earlier, such annual meeting.

F3 · derivative.expiration_date: Represents RSUs that shall vest and become nonforfeitable with respect to one-hundred percent (100%) of the total number of RSUs on the earlier of (i) 12 months from June 3, 2021 ("Grant Date") and (ii) the next regularly scheduled annual meeting of stockholders of the Issuer that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer as a director through such date or, if earlier, such annual meeting.

SEC source: 0001399529-21-000104 · wf-form4_162311596214632.xml · derivative · entry 2

Doberstein Stephen K · CIK 0001480111 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,333 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Common Stock.

F2 · derivative.exercise_date: Represents RSUs that vested and became nonforfeitable with respect to one-hundred percent (100%) of the total number of RSUs on June 3, 2021.

F2 · derivative.expiration_date: Represents RSUs that vested and became nonforfeitable with respect to one-hundred percent (100%) of the total number of RSUs on June 3, 2021.

SEC source: 0001399529-21-000104 · wf-form4_162311596214632.xml · nonDerivative · entry 1

Doberstein Stephen K · CIK 0001480111 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,333

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0000899243-20-016728 · doc4.xml · derivative · entry 2

Doberstein Stephen K · CIK 0001480111 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2030-06-14

F2 · derivative.exercise_date: This option vests monthly over 12 months from the Grant Date in substantially equal monthly installments, provided that the option vests in full on the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date or, if earlier, such annual meeting.

SEC source: 0000899243-20-016728 · doc4.xml · derivative · entry 1

Doberstein Stephen K · CIK 0001480111 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,333

Underlying: Common Stock · 3,333 shares

Expires not disclosed

F1 · derivative.exercise_price: Represents restricted stock units ("RSUs") that vest 12 months from June 15, 2020 ("Grant Date"), provided that these RSUs vest in full on the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer through such vesting date or, if earlier, such annual meeting. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock.

F1 · derivative.exercise_date: Represents restricted stock units ("RSUs") that vest 12 months from June 15, 2020 ("Grant Date"), provided that these RSUs vest in full on the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer through such vesting date or, if earlier, such annual meeting. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock.

F1 · derivative.expiration_date: Represents restricted stock units ("RSUs") that vest 12 months from June 15, 2020 ("Grant Date"), provided that these RSUs vest in full on the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer through such vesting date or, if earlier, such annual meeting. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0000899243-20-008529 · doc4.xml · derivative · entry 1

Doberstein Stephen K · CIK 0001480111 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2030-03-11

F1 · derivative.exercise_date: This option vests as to one-third of the underlying shares on the one year anniversary of the vesting start date of February 4, 2020 and as to the remaining two-thirds of the shares in eight quarterly installments thereafter, subject in each case to the Reporting Person's continued service on the board of directors of the Issuer through each applicable vesting date.

SEC source: 0001209191-19-048922 · doc4.xml · nonDerivative · entry 1

Doberstein Stephen K · CIK 0001480111 · SVP & Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,668

F1 · price: This transaction was executed in multiple trades at prices ranging from $17.18 to $17.30. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

SEC source: 0001209191-19-046714 · doc4.xml · nonDerivative · entry 1

Doberstein Stephen K · CIK 0001480111 · SVP & Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,668

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $17.87 to $18.37. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

SEC source: 0001209191-19-031184 · doc4.xml · nonDerivative · entry 1

Doberstein Stephen K · CIK 0001480111 · SVP & Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,913

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $30.86 to $32.68. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

SEC source: 0001209191-19-012332 · doc4.xml · nonDerivative · entry 1

Doberstein Stephen K · CIK 0001480111 · SVP & Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,374

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $41.90 to $42.96. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

SEC source: 0001209191-18-063297 · doc4.xml · derivative · entry 2

Doberstein Stephen K · CIK 0001480111 · SVP & Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,400

Underlying: Common Stock · 48,400 shares

Expires 2026-12-13

F2 · derivative.exercise_date: This stock option vests over four years in equal monthly installments based on continued service.

SEC source: 0001209191-18-063297 · doc4.xml · nonDerivative · entry 1

Doberstein Stephen K · CIK 0001480111 · SVP & Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 102,684

F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. These RSUs vest over three years in substantially equal quarterly installments based on continued service.

SEC source: 0001209191-18-059288 · doc4.xml · nonDerivative · entry 1

Doberstein Stephen K · CIK 0001480111 · SVP & Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,734

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $37.47 to $38.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

SEC source: 0001209191-18-047237 · doc4.xml · nonDerivative · entry 2

Doberstein Stephen K · CIK 0001480111 · SVP & Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,258

F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F3 · price: This transaction was executed in multiple trades at prices ranging from $56.37 to $59.72. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

SEC source: 0001209191-18-047237 · doc4.xml · derivative · entry 3

Doberstein Stephen K · CIK 0001480111 · SVP & Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2025-12-14

F4 · security: These options, at the time of their grant were subject to both performance-based and time-based vesting requirements. On August 15, 2018, the performance-based condition vesting was satisfied. The time-based vesting is on a monthly pro-rata basis over a period of four years from the grant date (December 15, 2017).

F5 · date: These stock options were granted on December 15, 2017 and the performance-based vesting requirement for these stock options was satisfied on August 15, 2018 upon the Compensation Committee's certification of the successful acceptance of the New Drug Application by the FDA for NKTR-181.

F6 · derivative.exercise_date: This stock option vests on a monthly pro-rata basis over a period of four years from the grant date.

SEC source: 0001209191-18-047237 · doc4.xml · nonDerivative · entry 1

Doberstein Stephen K · CIK 0001480111 · SVP & Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,959

F1 · security: Represents restricted stock units ("RSUs"), convertible on a one-for-one basis into shares of Common Stock of the Company. These RSUs, at the time of their grant on December 15, 2017, were subject to both performance-based and time-based vesting requirements. On August 15, 2018, the performance-based condition vesting was satisfied. The time-based vesting is on a quarterly pro-rata basis over a period of three (3) years from the date of grant.

SEC source: 0001209191-18-031589 · doc4.xml · nonDerivative · entry 1

Doberstein Stephen K · CIK 0001480111 · SVP & Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,959

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $81.35 to $84.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

SEC source: 0001209191-18-024451 · doc4.xml · derivative · entry 10

Doberstein Stephen K · CIK 0001480111 · SVP & Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 49,500 shares

Expires 2020-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-18-024451 · doc4.xml · nonDerivative · entry 6

Doberstein Stephen K · CIK 0001480111 · SVP & Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,394

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: This transaction was executed in multiple trades at prices ranging from $94.99 to $96.75. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

SEC source: 0001209191-18-024451 · doc4.xml · nonDerivative · entry 5

Doberstein Stephen K · CIK 0001480111 · SVP & Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,894

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-18-024451 · doc4.xml · derivative · entry 9

Doberstein Stephen K · CIK 0001480111 · SVP & Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,500

Underlying: Common Stock · 500 shares

Expires 2020-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-18-024451 · doc4.xml · derivative · entry 8

Doberstein Stephen K · CIK 0001480111 · SVP & Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 50,000 shares

Expires 2020-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-18-024451 · doc4.xml · derivative · entry 7

Doberstein Stephen K · CIK 0001480111 · SVP & Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 60,000 shares

Expires 2019-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-18-024451 · doc4.xml · nonDerivative · entry 4

Doberstein Stephen K · CIK 0001480111 · SVP & Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,394

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $89.98 to $94.99. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

SEC source: 0001209191-18-024451 · doc4.xml · nonDerivative · entry 3

Doberstein Stephen K · CIK 0001480111 · SVP & Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 177,894

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-18-024451 · doc4.xml · nonDerivative · entry 2

Doberstein Stephen K · CIK 0001480111 · SVP & Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 177,394

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-18-024451 · doc4.xml · nonDerivative · entry 1

Doberstein Stephen K · CIK 0001480111 · SVP & Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 127,394

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-18-011587 · doc4.xml · nonDerivative · entry 1

Doberstein Stephen K · CIK 0001480111 · SVP & Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,394

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $81.57 to $84.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

SEC source: 0001209191-17-066475 · doc4.xml · derivative · entry 2

Doberstein Stephen K · CIK 0001480111 · SVP & Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2025-12-14

F2 · derivative.exercise_date: This stock option vests over four years in equal monthly installments based on continued service.

SEC source: 0001209191-17-066475 · doc4.xml · nonDerivative · entry 1

Doberstein Stephen K · CIK 0001480111 · SVP & Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,820

F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. These RSUs vest over three years in substantially equal quarterly installments based on continued service.

SEC source: 0001209191-17-061588 · doc4.xml · nonDerivative · entry 2

Doberstein Stephen K · CIK 0001480111 · SVP & Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,820

F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F4 · price: This transaction was executed in multiple trades at prices ranging from $41.98 to $45.47. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

SEC source: 0001209191-17-061588 · doc4.xml · derivative · entry 3

Doberstein Stephen K · CIK 0001480111 · SVP & Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,750

Underlying: Common Stock · 43,750 shares

Expires 2024-12-12

F5 · security: These options, at the time of their grant were subject to both performance-based and time-based vesting requirements. On November 15, 2017, the performance-based condition vesting was satisfied. The time-based vesting is on a monthly pro-rata basis over a period of four years from the grant date (December 13, 2016).

F6 · date: These stock options were granted on December 13, 2016 and the performance-based vesting requirement for these stock options was satisfied on November 15, 2017 upon the Compensation Committee's certification of the successful acceptance of the New Drug Application by the FDA for Ciprofloxacin Dry Powder Inhalation (Cipro CPI).

F7 · derivative.exercise_date: This stock option vests on a monthly pro-rata basis over a period of four years from the grant date.